Ryan Deschner
Stock Analyst at Raymond James
(1.28)
# 3,362
Out of 4,711 analysts
6
Total ratings
50%
Success rate
-5.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Initiates: Outperform | $9 | $4.05 | +122.22% | 1 | Aug 30, 2024 | |
| LQDA Liquidia | Upgrades: Strong Buy | $27 | $11.10 | +143.24% | 2 | Aug 19, 2024 | |
| SPRY ARS Pharmaceuticals | Upgrades: Strong Buy | $18 → $22 | $11.18 | +96.78% | 2 | Aug 13, 2024 | |
| OMGA Omega Therapeutics | Initiates: Outperform | $12 | $0.84 | +1,333.86% | 1 | Jun 18, 2024 |
Trevi Therapeutics
Aug 30, 2024
Initiates: Outperform
Price Target: $9
Current: $4.05
Upside: +122.22%
Liquidia
Aug 19, 2024
Upgrades: Strong Buy
Price Target: $27
Current: $11.10
Upside: +143.24%
ARS Pharmaceuticals
Aug 13, 2024
Upgrades: Strong Buy
Price Target: $18 → $22
Current: $11.18
Upside: +96.78%
Omega Therapeutics
Jun 18, 2024
Initiates: Outperform
Price Target: $12
Current: $0.84
Upside: +1,333.86%